NanosiRNA COVID-19 : a specific antiviral treatment

MEDESIS PHARMA has a microemulsion technology allowing to deliver these native unmodified siRNAs directly into the cytoplasm of all cells of the body through the HDL lipoprotein receptors, with a passage of the BBB after a non-invasive oral administration.A very important element for clinical development: siRNA is invisible from the mouth to the delivery in the cytoplasm of the cells for the whole immune system because it is included in lipoproteins, and we do not trigger any immune response.

A pre-clinical study on a COVID animal model is underway.